施贵宝公司研发的免疫疗法组合Opdivo®与Yervoy®近日被加拿大安大略省快速通道医疗项目正式纳入报销范围，作为晚期肝细胞癌患者的一线治疗方案。这一决策使更多患者能够及时获得创新疗法的救治机会。
该组合疗法通过双重免疫机制激活患者自身免疫系统对抗肿瘤，其临床数据显著优于传统治疗方案。安大略省卫生部门指出，将创新药物纳入快速报销通道体现了医疗体系对晚期癌症患者迫切需求的积极响应。
此次纳入报销范围的决定预计将惠及省内数百名晚期肝癌患者。医疗专家强调，早期采用有效治疗方案对提升患者生存率和生活质量具有关键意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.